Novavax (NVAX) Liabilities and Shareholders Equity (2010 - 2026)

Novavax's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 19.32% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $4.7 billion, a 25.82% decrease from a year earlier, with the FY2025 full-year figure at $1.2 billion, down 24.6% from the prior year.
• Liabilities and Shareholders Equity eased to $1.0 billion in Q1 2026 per NVAX's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.8 billion in Q1 2022 and bottomed at $1.0 billion in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $1.7 billion (2023), against an average of $1.7 billion.
• Across the five-year window, Liabilities and Shareholders Equity gained 8.68% in 2022 and sank 45.58% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $2.3 billion in 2022, then declined by 20.42% to $1.8 billion in 2023, then fell by 13.19% to $1.6 billion in 2024, then slipped by 24.6% to $1.2 billion in 2025, then decreased by 11.33% to $1.0 billion in 2026.
• Per Business Quant, the three latest NVAX Liabilities and Shareholders Equity figures stand at $1.0 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025).